G. Jia

发表

Point-of-Care Measured Platelet Inhibition Correlates With a Reduced Risk of an Adverse Cardiac Event After Percutaneous Coronary Intervention: Results of the GOLD (AU-Assessing Ultegra) Multicenter Study

P. Teirstein, S. Steinhubl, G. Dangas, 2001, Circulation.

Effect of abciximab versus tirofiban on activated clotting time during percutaneous intervention and its relation to clinical outcomes--observations from the TARGET trial.

E. Topol, G. Stone, B. Meier, 2003, The American journal of cardiology.

Prognostic implication of activated partial thromboplastin time after reteplase or half-dose reteplase plus abciximab: results from the GUSTO-V trial.

E. Topol, P. Armstrong, H. White, 2005, European heart journal.

Impact of preprocedural white blood cell count on long term mortality after percutaneous coronary intervention: insights from the EPIC, EPILOG, and EPISTENT trials

Deepak L. Bhatt, E. Topol, A. Lincoff, 2003, Heart.

Effect of revascularization on mortality associated with an elevated white blood cell count in acute coronary syndromes.

Deepak L. Bhatt, E. Topol, S. Ommen, 2003, The American journal of cardiology.

The relationship of obesity to ischemic outcomes following coronary stent placement in contemporary practice

E. Topol, Jack L. Martin, H. Herrmann, 2006, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

Prognostic importance of physical examination for heart failure in non-St-elevation acute coronary syndromes the enduring value of Killip classification

U. Khot, Monica B. Khot, A. Lincoff, 2004 .

The inter-relationship between creatinine clearance, cardiac troponin T and outcomes in patients with acute coronary syndromes

R. Califf, E. Topol, M. Lauer, 2002 .

1138-43 Relationship of obesity to target vessel revascularization and other outcomes following coronary stenting: Observations from the TARGET trial

Jack L. Martin, H. Herrmann, S. Martin, 2004 .

Risk of intracranial haemorrhage with combined fibrinolytic and glycoprotein IIb/IIIa inhibitor therapy in acute myocardial infarction. Dichotomous response as a function of age in the GUSTO V trial.

R. Califf, E. Topol, P. Armstrong, 2003, European heart journal.

Prognostic importance of physical examination for heart failure in non-ST-elevation acute coronary syndromes: the enduring value of Killip classification.

E. Topol, U. Khot, Monica B. Khot, 2003, JAMA.

The relationship between baseline risk and mortality in ST-elevation acute myocardial infarction treated with pharmacological reperfusion: insights from the Global Utilization of Strategies To open Occluded arteries (GUSTO) V trial.

E. Topol, P. Armstrong, H. White, 2005, American heart journal.

Relation of an elevated white blood cell count after percutaneous coronary intervention to long-term mortality.

Deepak L. Bhatt, E. Topol, V. Rajagopal, 2004, The American journal of cardiology.

Outcome of acute ST-segment elevation myocardial infarction in diabetics treated with fibrinolytic or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: lessons from the GUSTO V trial.

R. Califf, E. Topol, P. Armstrong, 2004, Journal of the American College of Cardiology.

Troponin T levels in patients with acute coronary syndromes, with or without renal dysfunction.

R. Califf, E. Topol, M. Lauer, 2002, The New England journal of medicine.

Relation of polymorphisms in five genes to long-term aortocoronary saphenous vein graft patency.

S. Ellis, May M. Luke, J. Cassano, 2007, The American journal of cardiology.